August 9, 2023

Second Quarter
2023 Financial Results



3D SYSTEMS

Welcome and Participants

Dr. Jeffrey Graves
President & Chief Executive Officer

Michael Turner
Executive Vice President & Chief Financial Officer

Andrew Johnson
Executive Vice President, Chief Corporate Development Officer & Chief Legal Officer

Mick McCloskey
Vice President, Treasury & Investor Relations



To participate via phone, please dial:

1-201-689-8345

Forward Looking Statements

Certain statements made in this document that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward-looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. In particular, we note that there is no assurance that a definitive agreement for the transaction referenced in this document will be entered into or consummated or that integration will be successful, or synergies will be realized if such transaction were to be consummated. In addition, we note that Stratasys is not able to countersign a merger agreement with 3D Systems without first terminating Stratasys’ merger agreement with Desktop Metal and that the mutual consent of both Stratasys and Desktop Metal is necessary for termination of the Desktop Metal merger agreement. In addition, we note that Stratasys continues to recommend in favor of the Desktop Metal merger agreement, which remains in full force and effect, and that the vote by Stratasys shareholders on the Desktop Metal merger agreement has not yet occurred or been scheduled. Business combination proposals, transactions and integrations are subject to numerous risks and uncertainties. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as of the date of the statement. 3D Systems undertakes no obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances, or otherwise, except as required by law.

All references to the binding nature of the offer and merger agreement being proposed by 3D Systems, whether in a press release, presentation, other document or public statement, are subject to the contents of the escrow letter that has been delivered to Stratasys and will be on file publicly with the SEC.

Additional Information

This communication does not constitute an offer to buy or sell or the solicitation of an offer to sell or buy any securities. This communication relates to a proposal which 3D Systems has made for a business combination with Stratasys. In furtherance of this proposal and subject to future developments, 3D Systems (and, if a negotiated transaction is agreed, Stratasys) may file one or more registration statements, proxy statements or other documents with the SEC. This communication is not a substitute for any proxy statement, registration statement, prospectus or other document that 3D Systems and/or Stratasys may file with the SEC in connection with the proposed transaction.


Investors and security holders of 3D Systems and Stratasys are urged to read the proxy statement(s), registration statement, prospectus and/or other documents filed with the SEC carefully in their entirety if and when they become available as they will contain important information about the proposed transaction. Any definitive proxy statement(s) or prospectus(es) (if and when available) will be mailed to stockholders of 3D Systems and/or Stratasys, as applicable. Investors and security holders will be able to obtain free copies of these documents (if and when available) and other documents filed with the SEC by 3D Systems through the web site maintained by the SEC at http://www.sec.gov.

This document shall not constitute an offer to buy or sell or the solicitation of an offer to sell or buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended.

This communication is neither a solicitation of a proxy nor a substitute for any proxy statement or other filings that may be made with the SEC. Nonetheless, 3D Systems and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction. You can find information about 3D Systems' executive officers and directors in 3D Systems' definitive proxy statement filed with the SEC on April 5, 2023. Additional information regarding the interests of such potential participants will be included in one or more registration statements, proxy statements or other documents filed with the SEC if and when they become available. These documents (if and when available) may be obtained free of charge from the SEC's website at http://www.sec.gov.

Dr. Jeffrey Graves

President & Chief Executive Officer



Industry & Business Update

1

Scale is essential for the next era in Additive Manufacturing

2

Standalone 3D System's long-term growth strategy is clear

3

Fully committed to our high-potential Regenerative Medicine business

Our standalone plan expects high single-digit to low double-digit growth for non-dental markets in 2023 and a clear path for scale attainment by 2028

Combining with Stratasys allows for the immediate attainment of scale and value creation

An Incredibly Differentiated Position in Regenerative Medicine

3D Systems Bioprinting Leadership

35+ Years of developing advanced 3D printing applications

Organ development partnership since 2017


Acquired in 2021 to expand bioprinting capabilities

Human Organs (Lung, Kidney, and Liver)

Most Complex Object Ever 3D Printed:


- 2 Lobes
- 5,000 kilometers of vasculature
- 213 Million Alveoli
- 44 Trillion Voxels

2026 — **Targeting First in Human Trials (Lungs)**



3D printed human lung scaffold

Non-Organ Tissues



Vascularized Breast Tissue Scaffold
for Implantation & Cellularization

Drug Development

Bioprinted "Organ-on-a-chip"
can accurately replicate organ-specific drug response in pre-clinical drug trials





h-VIOS$_2$ chip with perfused vasculature


Progress in Systemic Bio

- Design Creation
- Bioprinting
- Lining Vasculatures with Cells
- Cell Survival with Perfusion in h-VIOS™ chip









Unique complexity, design control, scale and physiological relevance with 3D Systems bioprinting technology

An Expanding Systemic Bio Team



Located at the Texas Medical Center Innovation Factory Labs



State-of-the-art biomanufacturing facility with ISO 7 cleanroom

25

Scientists and engineers from top institutions worldwide

1,500+

Scaffolds printed in Q2 to support pharmaceutical collaborations

12,000+

Scaffold printing capacity per quarter, enabling support of additional contracts


An Exciting Partnership with Theradaptive

Spine  Spinal Fusion-Bone Repair ($2.0B US)


CMF *(personalized)*  CMF/Dental Repair ($1B US)

Orthopedics *(personalized)*  Trauma ($1B US)

Estimated addressable market of ~$4 billion



INACTIVE



ONE STEP SURFACE COATING

10 Minute process step



BIOACTIVE

Theradaptive's innovative protein-engineering technology, combined with 3D Systems' unique capability to produce personalized orthopedic implants combines each company's core strengths to accelerate market introduction

An Attractive Core Business Poised for Further Growth

Dental Solutions

- Industry working through high-levels of inventory
- Seeing stabilization of case volumes, not declines
- Exclusive supplier of #1 player in clear aligners space provides confidence in a segment rebound
- Business continues to perform in-line with expectations set in early FY'23; expecting more favorable comp for 2H'23



Dental & Orthodontic

Healthcare Solutions (excl. Dental)

- 7% year-over-year growth in 1H'23
- Driven by emergence of Virtual Surgical Planning and Orthopedic applications



Craniomaxillofacial



Virtual Surgical Planning



Orthopedic

Industrial Solutions

- 2% year-over-year growth in 1H'23
- Driven by market leadership in Aerospace & Defense and other key verticals



Transportation & Motor Sports



Aerospace & Defense



Semiconductor



Oil & Gas and Energy

Delivering year-to-date organic revenue growth in our non-dental markets

2023 Outlook

- ✓ Revising FY2023 guidance given elongated sales cycle and conservative customer capex spending
- ✓ Dental stabilization should bring more favorable comparisons in 2H'23
- ✓ Non-dental organic growth of high-single digit to low-double digit expected



Michael Turner


Chief Financial Officer



Year-to-Date Revenue Summary


($ in millions except percentages)

HSG




- ***Non-dental HSG grew ~7% year-to-date*** *driven by strength in Personalized Healthcare Solutions business*
- *Dental orthodontics business declined 35% year-to-date and* ***in-line with initial expectations***

ISG



- ***ISG revenues grew ~2% year-to-date*** *primarily driven by strength in Transportation & Motorsports, Foundries, Academic Research, and Aerospace & Defense verticals*


Consolidated



- *Year-to-date revenue declined 9% primarily driven by* ***expected headwinds in dental*** *orthodontics business*
- *Non-dental year-to-date revenue* ***grew over 3% and ~2% on a purely organic basis***

(1) Indicates YTD revenue growth in Non-Dental

Gross Profit Margin
(Non-GAAP)



Q2 2023 vs. Q2 2022

- Increase from PY primarily driven by mix, pricing and in-sourcing efforts

Q2 2023 vs. Q1 2023

- Flat QoQ with continued focus on cost optimization

See Appendix for a reconciliation of Non-GAAP Gross Profit Margin

Second Quarter Earnings

- **Adjusted EBITDA decreased to $(7) million in Q2 2023 compared to Q2 2022**
  - **Includes over $4 million invested in Regenerative Medicine**
- **Net loss of $(28.9) million**
- **Diluted loss per share of $(0.22), and diluted non-GAAP loss per share of $(0.07)**
- **Above results due to:**
  - Lower sales volumes particularly in dental orthodontics market
  - Continued investments in growth areas
  - Partial offset driven by cost optimization actions

See Appendix for a reconciliation of Adjusted EBITDA.
See Appendix for reconciliation of GAAP and Non-GAAP Net Loss per share.



Strong Balance Sheet

- Ended the quarter with $492 million dollars of cash and short-term investments on hand
- Sufficient cash to support organic growth, including Regenerative Medicine
- Continued focus on operational execution and integration of recent acquisitions

Full-Year 2023 Outlook

Metric	Guidance	Commentary
Revenue	**$525 - $545 million**	Expect **high-single to low-double digit organic growth** excl. dental markets
Non-GAAP GM%	**40% – 42%**	Continued execution on **cost efficiencies and fixed cost leverage** as sales ramp
Non-GAAP Adj. EBITDA	**Positive exiting Q4'23**	Continued execution on cost efficiencies while **maintaining $10M+ investment in Regenerative Medicine** business

*Continuing to target **full-year organic revenue growth in non-dental markets, enhanced margins and exiting the end of the year profitable**, while heavily investing in Regenerative Medicine to drive future growth potential*




Q&A Session

1-201-689-8345

Dr. Jeffrey Graves

President & Chief Executive Officer



Thank You

Find out more at:

www.3dsystems.com

Appendix

©2023 3D Systems, Inc. | All Rights Reserved.

Presentation of Information

3D Systems reports its financial results in accordance with GAAP. Management also reviews and reports certain non-GAAP measures, including: non-GAAP revenue excluding divestitures and on a constant currency basis (sometimes referred to as excluding divestitures and FX effects), non-GAAP Gross profit, non-GAAP Gross profit margin, non-GAAP Operating expenses, non-GAAP Operating (loss)/income, non-GAAP Interest and other income/(expense), net, non-GAAP Net income (loss), non-GAAP Basic and Diluted Income (Loss) per Share, adjusted EBITDA and adjusted EBITDA Margin. These non-GAAP measures exclude certain special items that management does not view as part of 3D Systems' underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Management believes that the non-GAAP measures provide useful additional insight into underlying business trends and results and provide a more meaningful comparison of period-over-period results. Additionally, management uses the non-GAAP measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. 3D Systems' non-GAAP measures are not calculated in accordance with or as required by GAAP and may not be calculated the same as similarly titled measures used by other companies. These non-GAAP measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.

A reconciliation of GAAP to non-GAAP financial measures is provided in the accompanying schedules in the Appendix.

3D Systems does not provide forward-looking guidance for certain measures on a GAAP basis. The company is unable to provide a quantitative reconciliation of forward-looking non-GAAP gross profit margins, Adjusted EBITDA and free cash flow to the most directly comparable forward-looking GAAP measures without unreasonable effort because certain items, including litigation costs, acquisition expenses, stock-compensation expense, intangible amortization expense, restructuring expenses, and goodwill impairment, are difficult to predict and estimate. These items are inherently uncertain and depend on various factors, many of which are beyond the company's control, and as such, any associated estimate and its impact on GAAP performance could vary materially.

Balance Sheets

3D Systems Corporation
Unaudited Consolidated Balance Sheets
June 30, 2023 and December 31, 2022

(in thousands, except par value)	June 30, 2023	December 31, 2022
ASSETS		
Current assets:		
Cash and cash equivalents	$ 490,444	$ 388,134
Short-term investments	1,135	180,603
Accounts receivable, net of reserves — $3,009 and $3,114	96,786	93,886
Inventories	156,153	137,832
Prepaid expenses and other current assets	40,395	33,790
Total current assets	784,913	834,245
Property and equipment, net	62,789	58,072
Intangible assets, net	85,130	90,230
Goodwill	387,934	385,312
Right-of-use assets	66,076	42,746
Deferred income tax asset	4,805	7,038
Other assets	40,050	28,970
Total assets	$ 1,431,697	$ 1,446,613
LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY		
Current liabilities:		
Current lease liabilities	$ 10,286	$ 9,036
Accounts payable	59,023	53,826
Accrued and other liabilities	47,239	55,571
Customer deposits	7,330	6,911
Deferred revenue	30,032	26,464
Total current liabilities	153,910	151,808
Long-term debt, net of deferred financing costs	450,848	449,510
Long-term lease liabilities	64,451	41,779
Deferred income tax liability	7,923	7,631
Other liabilities	41,610	44,181
Total liabilities	718,742	694,909
Redeemable non-controlling interest	1,951	1,760
Stockholders' equity:		
Common stock, $0.001 par value, authorized 220,000 shares; shares issued 133,504 and 131,207 as of June 30, 2023 and December 31, 2022, respectively	133	131
Additional paid-in capital	1,562,529	1,547,597
Accumulated deficit	(802,278)	(743,962)
Accumulated other comprehensive loss	(49,380)	(53,822)
Total stockholders' equity	711,004	749,944
Total liabilities, redeemable non-controlling interest and stockholders' equity	$ 1,431,697	$ 1,446,613

Statement of Operations

3D Systems Corporation
Unaudited Consolidated Statements of Operations
Three and Six Months Ended June 30, 2023 and 2022.

(in thousands, except per share amounts)	Three Months Ended June 30, 2023	Three Months Ended June 30, 2022	Six Months Ended June 30, 2023	Six Months Ended June 30, 2022
Revenue:				
Products	$ 89,165	$ 103,774	$ 173,553	$ 204,325
Services	39,029	36,271	75,877	68,721
Total revenue	128,194	140,045	249,430	273,046
Cost of sales:				
Products	56,135	65,331	106,015	123,803
Services	22,043	21,576	46,301	42,310
Total cost of sales	78,178	86,907	152,316	166,113
Gross profit	50,016	53,138	97,114	106,933
Operating expenses:				
Selling, general and administrative	58,983	64,404	117,268	119,819
Research and development	22,762	20,772	44,971	42,384
Total operating expenses	81,745	85,176	162,239	162,203
Loss from operations	(31,729)	(32,038)	(65,125)	(55,270)
Interest and other income (expense), net	3,214	329	7,089	(1,954)
(Loss) income before income taxes	(28,515)	(31,709)	(58,036)	(57,224)
(Provision) benefit for income taxes	(222)	(1,289)	(230)	(2,573)
(Loss) on equity method investment	(142)	—	(142)	—
Net (loss) income before redeemable non-controlling interest	(28,879)	(32,998)	(58,408)	(59,797)
Less: net (loss) income attributable to redeemable non-controlling interest	16	(37)	(92)	(37)
Net (loss) income attributable to 3D Systems Corporation	$ (28,895)	$ (32,961)	$ (58,316)	$ (59,760)
Net (loss) income per common share:				
Basic	$ (0.22)	$ (0.26)	$ (0.45)	$ (0.47)
Diluted	$ (0.22)	$ (0.26)	$ (0.45)	$ (0.47)
Weighted average shares outstanding:				
Basic	129,907	127,703	129,535	127,218
Diluted	129,907	127,703	129,535	127,218

Statement of Cash Flows

3D Systems Corporation
Unaudited Consolidated Statements of Cash Flows
Six Months Ended June 30, 2023, 2022

(in thousands)	Six Months Ended June 30, 2023	June 30, 2022
Cash flows from operating activities:		
Net (loss) income before redeemable non-controlling interest	$ (58,408)	$ (59,797)
Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities:		
Depreciation, amortization and accretion of debt discount	18,442	18,198
Stock-based compensation	18,282	20,061
Loss on short-term investments	6	—
Non-cash operating lease expense	4,025	—
Provision for inventory obsolescence and revaluation	4,550	97
Provision for bad debts	100	1,042
Loss (gain) on the disposition of businesses, property, equipment and other assets	57	—
Benefit for deferred income taxes and reserve adjustments	—	628
Loss on equity method investment	142	—
Asset impairment	1,187	24
Changes in operating accounts:		
Accounts receivable	(2,597)	(6,173)
Inventories	(24,469)	(16,609)
Prepaid expenses and other current assets	(4,556)	(2,981)
Accounts payable	4,381	6,168
Deferred revenue and customer deposits	1,870	(704)
Accrued and other liabilities	(6,836)	1,618
All other operating activities	(2,445)	217
Net cash (used in) provided by operating activities	(46,269)	(38,211)
Cash flows from investing activities:		
Purchases of property and equipment	(13,549)	(10,368)
Purchases of short-term investments	—	(384,450)
Sales and maturities of short-term investments	179,790	41,044
Acquisitions and other investments, net of cash acquired	(15,654)	(83,312)
Net cash provided by (used in) investing activities	150,587	(437,086)
Cash flows from financing activities:		
Debt issuance costs	—	(16)
Purchase of non-controlling interests	—	(2,300)
Taxes paid related to net-share settlement of equity awards	(4,564)	(10,047)
Other financing activities	(362)	(324)
Net cash (used in) provided by financing activities	(4,926)	(12,687)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	645	(2,047)
Net (decrease) increase in cash, cash equivalents and restricted cash	100,037	(490,031)
Cash, cash equivalents and restricted cash at the beginning of the year [a]	391,975	789,970
Cash, cash equivalents and restricted cash at the end of the period (a)	$ 492,012	$ 299,939

(a)The amounts for cash and cash equivalents and restricted cash shown above include restricted cash of $1,277 and $114 as of June 30, 2023 and December 31, 2022, respectively, which are included in prepaid expenses and other current assets. In addition, included in cash and cash equivalents and restricted cash above as of June 30, 2023 and December 31, 2022 is $291 and $3,727, respectively, of restricted cash, which, is included in other non-current assets. The amounts for cash and cash equivalents and restricted cash shown above include restricted cash of $1,105 and $313 as of June 30, 2022 and December 31, 2021, respectively.

Reconciliation of Revenue to Non-GAAP Revenue

(in thousands except percentages, unaudited)

3D Systems Corporation
Unaudited Reconciliations of GAAP to Non-GAAP Measures
Three and Six Months Ended June 30, 2023 and 2022.

Constant Currency Revenue [4]

	Three Months Ended June 30,				Constant Currency [3]	
(in thousands)	2023	2022	$ Change	% Change	FX Effect [2]	% Change [3]
Healthcare Solutions	$ 60,874	71,746	$ (10,872)	(15.2)%	$ 181	(15.4)%
Industrial Solutions	67,320	68,299	(979)	(1.4)%	193	(1.7)%
Total revenue	$ 128,194	$ 140,045	$ (11,851)	(8.5)%	$ 374	(8.7)%

[1] To assist in the analysis of the Company's revenue trends, the Company estimated the impact of foreign exchange on year-over-year revenue growth by recasting revenue for the three months ended June 30, 2023 by applying the foreign exchange rates used to translate 2022 non-US functional currency revenue to 2023 non-US functional currency revenue.
[2] Represents the estimated impact on "as reported" revenue due to changes in foreign currency exchange rates
[3] Represents the % increase or decrease in revenue excluding the estimated "FX effect"
[4] Amounts in table may not foot due to rounding

	Six Months Ended June 30,				Constant Currency [3]	
(in thousands)	2023	2022	$ Change	% Change	FX Effect [2]	% Change [3]
Healthcare Solutions	$ 109,599	$ 136,091	$ (26,492)	(19.5)%	$ (383)	(19.2)%
Industrial Solutions	139,831	136,955	2,876	2.1%	(2,303)	3.8%
Total revenue	$ 249,430	$ 273,046	$ (23,616)	(8.6)%	$ (2,686)	(7.7)%

[1] To assist in the analysis of the Company's revenue trends, the Company estimated the impact of foreign exchange on year-over-year revenue growth by recasting revenue for the six months ended June 30, 2023 by applying the foreign exchange rates used to translate 2022 non-US functional currency revenue to 2023 non-US functional currency revenue.
[2] Represents the estimated impact on "as reported" revenue due to changes in foreign currency exchange rates
[3] Represents the % increase or decrease in revenue excluding the estimated "FX effect"
[4] Amounts in table may not foot due to rounding

Gross Profit and Gross Profit Margin Reconciliation

(in thousands except percentages, unaudited)

Gross Profit and Gross Profit Margin [1]

(in thousands)	Three Months Ended June 30,			
	2023		2022	
	Gross Profit	Gross Profit Margin	Gross Profit	Gross Profit Margin
GAAP	$ 50,016	39.0%	$ 53,138	37.9%
Amortization expense included in Cost of sales	(122)		136	
Non-GAAP [2]	$ 49,894	38.9%	$ 53,274	38.0%

[1] Amounts in table may not foot due to rounding

[2] Calculated as non-GAAP gross profit as a percentage of total revenue.

(in thousands)	Six Months Ended June 30,			
	2023		2022	
	Gross Profit	Gross Profit Margin	Gross Profit	Gross Profit Margin
GAAP	$ 97,114	38.9%	$ 106,933	39.2%
Amortization expense included in Cost of sales	14		276	
Non-GAAP [2]	$ 97,128	38.9%	$ 107,209	39.3%

[1] Amounts in table may not foot due to rounding

[2] Calculated as non-GAAP gross profit as a percentage of total revenue.

Adjust EBITDA reconciliation

(in thousands except percentages, unaudited)

3D Systems Corporation
Unaudited Reconciliations of GAAP to Non-GAAP Measures
Three and Six Months Ended June 30, 2023 and 2022.

Net (Loss) Income to Adjusted EBITDA [1]

	Three Months Ended June 30,		Six Months Ended June 30,	
(in thousands)	2023	2022	2023	2022
Net (loss) income attributable to 3D Systems Corporation	**$ (28,895)**	**$ (32,961)**	**$ (58,316)**	**$ (59,760)**
Interest (income) expense, net	(4,404)	(1,825)	(8,209)	(1,990)
Provision for income taxes	222	1,289	230	2,573
Depreciation expense	5,294	5,032	10,606	10,850
Amortization expense	3,258	3,303	6,497	5,980
EBITDA	(24,525)	(25,162)	(49,192)	(42,347)
Stock-based compensation expense	7,990	7,403	18,282	20,061
Acquisition and divestiture-related expense	1,512	2,972	4,188	6,654
Legal expense	2,656	10,760	2,735	10,773
Restructuring expense	4,121	(10)	5,824	301
Redeemable non-controlling interest	16	(37)	(92)	(37)
Loss on equity method investment	142	—	142	—
Other non-operating (income) expense, net	1,190	1,496	1,120	3,944
Adjusted EBITDA	**$ (6,898)**	**$ (2,578)**	**$ (16,993)**	**$ (651)**

[1] Amounts in table may not foot due to rounding

Earnings per Share Reconciliation

(in dollars, unaudited)

3D Systems Corporation
Unaudited Reconciliations of GAAP to Non-GAAP Measures
Three and Six Months Ended June 30, 2023 and 2022.

Diluted (Loss) Income per Share [1]

	Three Months Ended June 30,		Six Months Ended June 30,	
(in dollars)	2023	2022	2023	2022
Diluted (loss) income per share	$ (0.22)	$ (0.26)	$ (0.45)	$ (0.47)
Stock-based compensation expense	0.06	0.06	0.14	0.16
Amortization expense	0.03	0.03	0.05	0.05
Acquisition and divestiture-related expense	0.01	0.02	0.03	0.05
Legal expense	0.02	0.08	0.02	0.08
Restructuring expense	0.03	—	0.05	—
Non-GAAP diluted (loss) income per share	$ (0.07)	$ (0.07)	$ (0.16)	$ (0.12)

[1] Amounts in table may not foot due to rounding